A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
Year: 2009
Type: conference-abstract
Source: Clinical Lymphoma & Myeloma
Authors: PG Richardson, S Lonial, A Jakubowiak, S Jagannath, N Raje, D Avigan, IM Ghobrial, R Schlossman, A Mazumder, NC Munshi, D Vesole, R Joyce, D Doss, D Warren, L Lunde, R Lukas, S Kaster, K Shea, C Delaney, M Lauria, C Mitsiades, T Hideshima, R Knight, DL Esseltine, KC Anderson
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2016537588